Corbus Pharmaceuticals presented Phase 1 data on CRB-701 at ASCO GU, showing safety, tolerability, and responses across multiple tumor types.

Inc. (current market capitalization: $1.18 billion) has announced a revised compensation package for its Chairman, President, and Chief Executive Officer, Pravin Dugel, M.D., effective from February ...

Patients with diabetic DED can experience inflammatory biomarker reductions and sign and symptom improvements with topical insulin.

Routine evaluation of meibomian glands, starting in childhood, is crucial for identifying and managing this progressive ...

Morning Pointe Senior Living announces Fred Hutagaol has been selected as the recipient of the Morning Pointe Scholars Endowment scholarship at Southern Adventist University. “The Morning ... more ...

A cervical cancer drug may elevate the risk of developing ocular surface disease, such as conjunctival scarring and infectious keratitis.

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

LONDON and NEW YORK - OKYO Pharma Limited (NASDAQ: OKYO), a biopharmaceutical company specializing in the development of treatments for ocular conditions and currently valued at $37 million, has ...

The USAN designation reflects Okyo Pharma’s commitment to developing new therapies for unmet medical needs in ophthalmology. The suffix “-mod” in urcosimod denotes its classification as a modulator of ...

A study found that injecting mesenchymal stem cells into periocular tissue effectively reduces eye inflammation without ...

GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN –– Approval based on positive data ...